Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Diamedica Therapeutics Inc
(NQ:
DMAC
)
2.420
-0.070 (-2.81%)
Streaming Delayed Price
Updated: 1:07 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
15,680
Open
2.490
Bid (Size)
2.420 (2)
Ask (Size)
2.510 (5)
Prev. Close
2.490
Today's Range
2.420 - 2.541
52wk Range
1.500 - 4.750
Shares Outstanding
37,953,711
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
April 17, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
March 19, 2024
DMAC stock results show that DiaMedica Therapeutics met analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Performance
YTD
-14.49%
-14.49%
1 Month
-14.18%
-14.18%
3 Month
-15.09%
-15.09%
6 Month
+15.79%
+15.79%
1 Year
+41.52%
+41.52%
More News
Read More
Recap: DiaMedica Therapeutics Q4 Earnings
March 19, 2024
Via
Benzinga
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
March 19, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
January 29, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Earnings Outlook For DiaMedica Therapeutics
November 10, 2023
Via
Benzinga
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
January 22, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
November 13, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
November 09, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
November 06, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Earnings Scheduled For November 13, 2023
November 13, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
October 25, 2023
Via
InvestorPlace
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
September 12, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
September 06, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
August 14, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
August 08, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
July 18, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Three (3) Stocks Under $10 That Insiders Are Buying
July 05, 2023
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement
June 26, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
June 22, 2023
Via
Benzinga
DiaMedica Raises $37.5M Via Equity Offering, Aiding Development Activities For DM199
June 21, 2023
Via
Benzinga
DiaMedica Therapeutics Announces $37.5 Million Private Placement
June 21, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
June 21, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
May 30, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results
May 15, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.